BTRC and cancer: Many novel strategies such as the targeting of β-TrCP-NRF2, the HRD1–NRF2 binding or developing PROTACs (proteolysis-targeting chimeras) to promote NRF2 proteasomal degradation, should be examined to expand the armamentarium to be used in cancer prevention and therapy.